A carregar...
Publicação
The role of PD-L1 expression in pituitary tumours: lessons from the current literature
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 291.36 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Background: Programmed cell death-1 (PD-1) and PD ligand-1 (PD-L1) expression predict the biological behaviour, aggressiveness, and response to immune checkpoint inhibitors in different cancers. We reviewed the published data on PD-L1 expression in pituitary tumours from the perspective of its biological role and prognostic usefulness.
Summary: A literature review focused on PD-L1 expression in pituitary tumours was performed. Six immunohistochemistry-based studies which assessed PD-L1 positivity in pituitary tumours were included, encompassing 704 patients. The cohort consisted of 384 (54.5%) nonfunctioning tumours and 320 (43.5%) functioning pituitary tumours. PD-L1 expression was positive in 248 cases (35.2%). PD-L1 positivity rate was higher in functioning than in nonfunctioning tumours (46.3% vs. 26.0%; p < 0.001) but also higher in growth hormone-secreting tumours (56.7%) and prolactinomas (53.6%) than in thyrotroph (33.3%) or corticotroph tumours (20.6%). While proliferative pituitary tumours showed higher rate of PD-L1 positivity than non-proliferative tumours (p < 0.001), no association with invasion or recurrence was found.
Key messages: PD-L1 is expressed in a substantial number of pituitary tumours, predominantly in the functioning ones. PD-L1 positivity rates were significantly higher in proliferative pituitary tumours in comparison to non-proliferative tumours, but no differences were found concerning invasive or recurrent pituitary tumours. More studies following homogeneous and standardised methodologies are needed to fully elucidate the role and usefulness of PD-L1 expression in pituitary tumours.
Descrição
© 2024 S. Karger AG, Basel
Palavras-chave
Immune checkpoint inhibitors Immunotherapy Nivolumab Pembrolizumab Pituitary adenoma Pituitary tumour Programmed cell death ligand 1 Tumour microenvironment
Contexto Educativo
Citação
Neuroendocrinology. 2024 May 16:1-12
Editora
Karger